NYSE-listed shares of Novo Nordisk (NVO) traded over 1% lower on Friday afternoon after Bank of America lowered its price ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...

Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...

NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

Novo Nordisk is betting on the future with a $2-billion deal to buy rights to a Chinese obesity drug. But investors remain unimpressed.

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time ...

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...

BofA analysts expect Novo Nordisk’s first-quarter sales to reach 77 billion Danish kroner (DKK), a 17% year-over-year ...